Evidence map›Paper›PMID 39742881›Full record

ArticleYonsei medical journal2025

Comparison of Patients Who Were Not Evaluated and Lost to Follow-Up with Multidrug/Rifampin-Resistant Tuberculosis in South Korea.

Hongjo Choi, Jeongha Mok, Young Ae Kang, Dawoon Jeong, Hee-Yeon Kang, Hee Jin Kim, Hee-Sun Kim, Doosoo Jeon

Abstract readComparative Study
In one paragraph

Article in Yonsei medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hongjo ChoiDivision of Health Policy and Management, Korea University College of Health Science, Seoul, Korea.ORCID https://orcid.org/0000-0001-8853-7061
Jeongha MokDepartment of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.ORCID https://orcid.org/0000-0001-7406-1373
Young Ae KangDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-7783-5271
Dawoon JeongDepartment of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-6260-0277
Hee-Yeon KangDepartment of Cancer Control and Population Health, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Korea.ORCID https://orcid.org/0000-0001-8530-8087
Hee Jin KimCentral Training Institute, Korean National Tuberculosis Association, Seoul, Korea.ORCID https://orcid.org/0000-0002-0128-2789
Hee-Sun KimDepartment of Health Policy Research, National Evidence-Based Healthcare Collaborating Agency, Seoul, Korea.ORCID https://orcid.org/0000-0003-4836-907X
Doosoo JeonDepartment of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea. sooli10@hanmail.net.ORCID https://orcid.org/0000-0002-8206-9487

Funding

National Evidence-based Healthcare Collaborating Agency NC19-002National Evidence-based Healthcare Collaborating Agency NC20-003National Evidence-based Healthcare Collaborating Agency NC21-001
6 · The paper itself

Abstract

purposeThis study aimed to evaluate the prognosis of the not evaluated (NE) group by comparing it with the lost to follow-up (LTFU) group among patients with multidrug/rifampin-resistant tuberculosis (MDR/RR-TB). MATERIALS AND

methodsThis was a retrospective longitudinal follow-up study using an integrated database constructed by data linkage of the three national databases. This database included 7226 cases of MDR/RR-TB notified between 2011 and 2017 in South Korea.

resultsAmong the 7226 MDR/RR-TB cases, 730 (10.1%) were classified as LTFU group, and 353 (4.9%) as NE group. When comparing NE group with LTFU group, there were no significant differences in the all-cause mortality rate (18.1% vs. 13.8%,

conclusionNE group had an unfavorable outcome comparable to LTFU group, suggesting undetected cases of LTFU or deaths during the referral process. Establishing an efficient patient referral system would contribute to reducing the incidence of NE cases.

Indexed as

Lost to Follow-UpTuberculosis, Multidrug-ResistantAdultAgedAntitubercular AgentsFemaleFollow-Up StudiesHumansLongitudinal StudiesMaleMiddle AgedPrognosisRepublic of KoreaRetrospective StudiesRifampinAntitubercular AgentsRifampinlost to follow-upmortalitypatient transferretreatmentrisk factorsTuberculosis, multidrug-resistant

Identifiers

PMID39742881
PMCPMC11704241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.